Full-Time

Technical Accounting Director

Superluminal Medicines

Superluminal Medicines

51-200 employees

ML-driven design of candidate small molecules

No salary listed

Boston, MA, USA

In Person

Bachelor's

Category
Accounting (2)
,

Get referred to Superluminal Medicines

See people who can refer or advise you

Requirements
  • Bachelor's degree in Accounting, Finance, or a related field, or equivalent combination of education and relevant professional experience.
  • Active Certified Public Accountant (CPA) license.
  • 5+ years of progressive technical accounting, external reporting, or financial reporting
  • Experience working in a publicly traded company environment.
  • Knowledge of U.S. Generally Accepted Accounting Principles (U.S. GAAP), including applying accounting guidance to complex business transactions.
  • Experience preparing technical accounting analyses, accounting position papers, and financial statement disclosures.
  • Experience serving as a primary contact or key liaison for external auditors during financial statement audits (e.g. Big Four)
  • Ability to research accounting issues, evaluate alternatives, document conclusions, and communicate accounting positions to finance and non-finance stakeholders.
  • Ability to prepare written analyses and communicate accounting concepts in a clear and understandable manner to senior management
  • Ability to organize work, manage multiple priorities, and meet established deadlines in a changing business environment.
Responsibilities
  • Serve as the company’s technical accounting subject matter expert, providing guidance on complex accounting matters and transactions.
  • Research, evaluate, and document accounting conclusions in accordance with U.S. GAAP.
  • Prepare and maintain technical accounting memoranda, accounting position papers, and supporting documentation for significant accounting matters
  • Evaluate accounting implications of complex transactions, including collaboration arrangements, revenue recognition, equity transactions, stock-based compensation, debt, financing arrangements, leases, and other strategic initiatives.
  • Develop, maintain, and update accounting policies and procedures that promote consistent application of accounting guidance across the organization.
  • Monitor emerging accounting standards and assess their impact on financial reporting and business operations.
  • Lead preparation and review of quarterly and annual external financial reporting, including financial statements, footnote disclosures, supporting schedules, and related reporting packages
  • Manage the financial reporting calendar and coordinate with cross-functional partners to ensure accurate and timely reporting.
  • Support preparation of external reporting materials and financial disclosures.
  • Develop processes and documentation to support efficient and scalable financial reporting.
  • Partner with Finance leadership to enhance reporting processes, improve transparency, and support evolving business needs.
  • Serve as a key point of contact for external auditors and manage audit activities related to technical accounting, financial reporting, and disclosures.
  • Coordinate audit requests, prepare supporting documentation, and ensure timely resolution of audit questions.
  • Support the design, implementation, and enhancement of internal controls and accounting processes.
  • Identify opportunities to improve accounting operations, strengthen controls, and increase efficiency.
  • Partner with Accounting and Finance team members to establish best practices and scalable processes.
  • Serve as a trusted finance partner to business leaders by providing thoughtful accounting guidance and helping teams understand the financial implications of key decisions.
  • Partner closely with Legal, Business Development, Operations, Research & Development, and Finance teams to evaluate accounting considerations related to business activities.
  • Act as an educator and translator, simplifying complex accounting concepts and providing practical guidance to non-finance partners.
  • Support the implementation and optimization of financial reporting tools, including reporting systems and disclosure management platforms.
  • Develop strong relationships across the organization and contribute to a culture of collaboration, accountability, and continuous improvement.
Desired Qualifications
  • Experience in a clinical-stage biotech, pharmaceutical, or other life sciences organization.
  • Experience with complex collaboration arrangements, revenue recognition, equity transactions, stock-based compensation, and financing transactions.
  • Experience supporting financial reporting processes within a public company environment (e.g. SEC)
  • Experience with Workiva, Active Disclosure, or similar financial reporting and disclosure management software.
  • Experience implementing or enhancing accounting processes, controls, and reporting infrastructure.
  • Familiarity with ERP systems (i.e. NetSuite)
  • Experience supporting company growth, strategic transactions, or other complex business initiatives.
Superluminal Medicines

Superluminal Medicines

View

Superluminal Medicines develops small-molecule drug discovery solutions by combining deep biology, chemistry, and machine learning. It creates candidate-ready compounds with high speed and accuracy, using a proprietary big data platform and predictive design models to model protein shapes and design selective compounds that induce precise structural changes for therapeutic effects. The company collaborates with pharmaceutical and biotech firms, licensing its technology and pursuing milestone-based payments, rather than selling products outright. This partnership-centric model helps clients accelerate their drug discovery programs in a highly competitive market. The company aims to shorten the path from target to clinical candidate by delivering well-characterized, selective small molecules efficiently.

Company Size

51-200

Company Stage

Series A

Total Funding

$153M

Headquarters

Boston, Massachusetts

Founded

2023

Get referred to Superluminal Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Lilly's February 2026 update reaffirmed up to $1.3B in payments.
  • Superluminal expects an IND submission in late 2026 for obesity.
  • RA Capital, Insight, NVentures, Catalio, and Lilly funded the $120M Series A.

What critics are saying

  • Lilly gets exclusive rights, so Superluminal loses downstream economics.
  • The lead obesity asset still needs 2026 human data after IND filing.
  • A failed MC4R program would crush platform credibility and future partnering.

What makes Superluminal Medicines unique

  • Superluminal combines protein dynamics, structural biology, and ML on GPCRs.
  • Lilly backed the 2024 Series A and signed a 2025 $1.3B pact.
  • Its lead MC4R obesity program entered IND-enabling studies in July 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Hybrid Work Options

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Wellness Program

Mental Health Support

Gym Membership

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Parental Leave

Relocation Assistance

Employee Referral Bonus

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Training Programs

Tuition Reimbursement

Meal Benefits

Commuter Benefits

Pet Insurance

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

31%

1 year growth

31%

2 year growth

31%
The Pharma Letter
Aug 15th, 2025
Lilly and Superluminal work on GPCR drugs for cardiometabolic diseases

Eli Lilly (NYSE: LLY) has entered into a collaboration with Boston-based Superluminal Medicines to develop small-molecule therapies for undisclosed G protein-coupled receptor (GPCR) targets linked to cardiometabolic diseases and obesity.

Fierce Biotech
Aug 14th, 2025
Superluminal secures $1.3B pact with backer Lilly to develop cardiometabolic, obesity drugs

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech. | Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech.

BioWorld
Aug 14th, 2025
Superluminal, Lilly in $1.3B Deal

Superluminal Medicines Inc. has entered a collaboration with Eli Lilly and Co. in a deal worth up to $1.3 billion. The partnership aims to develop therapies for cardiometabolic diseases and obesity by targeting undisclosed G protein-coupled receptors. The deal includes up-front and near-term investments, an equity investment, development and commercial milestones, and tiered royalties on net sales.

BioWorld
Aug 14th, 2025
Superluminal joins a $1.3B deal with series A backer Lilly

Superluminal Medicines Inc. and Eli Lilly and Co. are collaborating in a deal to develop cardiometabolic disease and obesity therapies by aiming at undisclosed G protein-coupled receptor targets.

FinSMEs
Sep 9th, 2024
Superluminal Medicines Closes $120M Series A Funding

Superluminal Medicines, a Boston, MA-based company that uses generative biology, chemistry and machine learning approaches to create medicines, raised $120M in Series A funding